Urothelial Cancer

Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum

Summary: GENEXOL® PM is a novel Cremo-phor® EL (CrEL)-free polymeric micelle formulation of paclitaxel. This multicenter phase II study was designed to evaluate the efficacy and safety of GENEXOL® PM  monotherapy in patients with advanced urothelial carcinoma who developed disease progression after gemcitabine and cisplatin combination chemotherapy.

Brand Name: PAXUS™ PM (South East Asia), GENEXOL® PM (Korea & other territories)